Loading
A phase 1/2 trial of HDM2017, Bevacizumab, CAPOX in colorectal cancer, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07805551 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 220 participants planned, started 2026-08-18 and due to reach its primary completion in 2030-08. Interventions recorded: HDM2017, Bevacizumab, Oxaliplatin, Fluorouracil, Capecitabine. Conditions listed: CRC, Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Bevacizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.